Laura Berner

Laura Berner has extensive biopharma industry experience, in leadership roles spanning corporate strategy, business development, investor relations and law. She currently serves as Chief Operating Officer at TRexBio, a private, venture-backed biotech company, with responsibility for the company’s corporate and operational functions. Previously, Ms. Berner was Vice President, Head of Business Development & Investor Relations at Myovant Sciences, where she led the execution of global partnerships for the commercialization of the company’s lead products Myfembree® (relugolix, estradiol and norethindrone acetate) and Orgovyx® (relugolix) and supported the company through multiple follow-on financings. Earlier in her career, she was a member of the business development team at Roche Pharma Partnering, and the transactional law group at Genentech. Ms. Berner began her career as a corporate attorney first at Ropes & Gray LLP, and later in the Office of the General Counsel at Harvard University, advising on general corporate, business development and strategic transactions.